Low dose cytosine arabinoside in the treatment of acute non-lymphocytic leukaemia
- 24 April 2009
- journal article
- research article
- Published by Wiley in Scandinavian Journal of Haematology
- Vol. 34 (3) , 261-263
- https://doi.org/10.1111/j.1600-0609.1985.tb02789.x
Abstract
Complete remissions were obtained with low dose cytosine arabinoside (ARA-C) in 8 of 21 previously untreated patients with ANLL > 60 yr of age and in 2 of 4 previously treated patients < 60 yr of age. Seven of the patients remain in remission after 1-26 mo. Low dose ARA-C with rather low toxicity may induce remissions in elderly patients with ANLL.Keywords
This publication has 15 references indexed in Scilit:
- Low-dose cytosine-arabinoside in the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)Annals of Hematology, 1984
- Response of Preleukemic Syndromes to Continuous Infusion of Low-Dose CytarabineNew England Journal of Medicine, 1983
- Does treatment with ARA-C in low dosage cause differentiation of leukemic cells?Blood, 1983
- Low dose arabinosyl cytosine for treatment of myelodysplastic syndromes and subacute myeloid leukemiaLeukemia Research, 1983
- Short-term treatment for acute myelogenous leukaemia.BMJ, 1982
- High-dose combination chemotherapy for acute nonlymphoblastic leukemia in adultsCancer, 1981
- DIFFERENTIATION OF MYELOID LEUKAEMIC CELLS: NEW POSSIBILITIES FOR THERAPYBritish Journal of Haematology, 1979
- Treatment of acute nonlymphocytic leukemia: use of anthracycline- cytosine arabinoside induction therapy and comparison of two maintenance regimensBlood, 1979
- HIGH REMISSION-INDUCTION RATE IN ACUTE MYELOID LEUKÆMIAThe Lancet, 1977
- Proposals for the Classification of the Acute Leukaemias French‐American‐British (FAB) Co‐operative GroupBritish Journal of Haematology, 1976